Comparison of the efficacy of intralesional bleomycin versus intralesional triamcinolone acetonide in the treatment of keloids

Dermatol Ther. 2019 Sep;32(5):e13036. doi: 10.1111/dth.13036. Epub 2019 Aug 8.

Abstract

Keloid is characterized by benign overgrowth of dermal collagen in response to skin injury in genetically predisposed individuals. Intralesional triamcinolone and bleomycin have been used with varying success in the treatment of keloids. To compare the efficacy of intralesional triamcinolone versus intralesional bleomycin in the treatment keloids. A total of 164 patients were randomized into two of 82 each. Group A received intralesional bleomycine and Group B received intralesional triamcinolone. Patients were scored at baseline and at the end of treatment for therapeutic response based on reduction on patient and observer scar assessment scale (POSAS). Mean baseline POSAS score was 91 ± 10.98 SD check in Group A and 90 ± 10.85 SD in Group B. POSAS score after 24 weeks 26 SD ± 11.91 in Group and 34 ± 12.28 in Group B. This difference was statistically difference. Intralesional bleomycin is more efficacious than intralesional triamcinolone acetonide in the treatment of keloids.

Keywords: intralesional bleomycin; intralesional triamcinolone; keloids.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antibiotics, Antineoplastic / administration & dosage
  • Bleomycin / administration & dosage*
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Glucocorticoids / administration & dosage
  • Humans
  • Injections, Intralesional
  • Keloid / diagnosis
  • Keloid / drug therapy*
  • Male
  • Retrospective Studies
  • Skin / pathology
  • Treatment Outcome
  • Triamcinolone Acetonide / administration & dosage*

Substances

  • Antibiotics, Antineoplastic
  • Glucocorticoids
  • Bleomycin
  • Triamcinolone Acetonide